Open AccessTriple Negative Breast Cancer – An Overview
Author(s) -
Kartik Aysola,
Akshata Desai,
Crystal Welch,
Jianmin Xu,
Yuchu Qin,
Vaishali Reddy,
Roland Matthews,
Charlotte D. Owens,
Joel Okoli,
Derrick J. Beech,
Chandrika J. Piyathilake,
Shyam Reddy,
V. N. Rao
Publication year - 2012
Publication title -
hereditary genetics
Language(s) - English
Resource type - Journals
ISSN - 2161-1041
DOI - 10.4172/2161-1041.s2-001
Subject(s) - triple negative breast cancer , breast cancer , progesterone receptor , estrogen receptor , cancer research , immunohistochemistry , targeted therapy , medicine , oncology , cancer , epidermal growth factor receptor , biology
Triple Negative Breast Cancer (TNBC) is a heterogeneous disease that based on immunohistochemistry (IHC) is estrogen receptor (ER) negative, progesterone receptor (PR) negative and human epidermal growth factor receptor 2 (HER2) negative. TNBC is typically observed in young AA women and Hispanic women who carry a mutation in the BRCA1 gene. TNBC is characterized by a distinct molecular profile, aggressive nature and lack of targeted therapies. The purpose of this article is to review the current and future novel signalling pathways as therapeutic approaches to TNBC. Recent Identification of a new BRCA1 trafficking pathway holds promise in the future for the development of targeted therapies for TNBC.